Tuesday, June 10, 2014 6:20:24 PM
I viewed the several NWBO PRs and 10Qs and felt it was apparent that the trials had not yet started. I believe it was a point of discussion on this board that the HE would impact the planned trials at the various centers of excellence.
In the last 5 years I have invested in 6 bio-tech companies.(all speculative with phase 2 or 3 trials underway) Out of the 6, NWBO has been the most "to the point" in its PRs and its corporate communications. There are no wasted words or "pumping" of the stock by management. When LP chooses to defend the company it is well placed and again "to the point". She chooses to set the record straight and as the "ultimate long" defend the integrity of the company.
I view today's PR and the subsequent analysis from this board as evidence that "the shingle is hung" in Germany and now we can clearly see the implementation of the company's strategy unfolding.
Gentlemen, we have a product to sell and can now say we are in business in Germany.
In the last 5 years I have invested in 6 bio-tech companies.(all speculative with phase 2 or 3 trials underway) Out of the 6, NWBO has been the most "to the point" in its PRs and its corporate communications. There are no wasted words or "pumping" of the stock by management. When LP chooses to defend the company it is well placed and again "to the point". She chooses to set the record straight and as the "ultimate long" defend the integrity of the company.
I view today's PR and the subsequent analysis from this board as evidence that "the shingle is hung" in Germany and now we can clearly see the implementation of the company's strategy unfolding.
Gentlemen, we have a product to sell and can now say we are in business in Germany.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
